Go East: The Rise of China's Cancer Medicines and CAR-T Therapy

China is developing cancer medicines used around the world—and opening new treatment pathways at home. For patients facing a cancer that has returned, a difficult molecular target or the cost of continuing treatment, Chinese innovation deserves a closer look.¹

Evidence reviewed: 31 October 2026; armoured-DC update: 3 November 2026.

1. Chinese cancer-drug innovation has arrived on the world stage

The scale of China's pharmaceutical progress is striking:

• 46% growth in research spending. Reported R&D expenditure by pharmaceutical manufacturers rose from CNY 78.46 billion in 2020 to CNY 114.56 billion in 2024.²
• 76 innovative medicines approved in 2025, up from 48 in 2024—a 58% increase across therapeutic areas.³
• More than USD 130 billion in overseas licensing deals in 2025, across more than 150 transactions—up from USD 51.9 billion and 94 deals in 2024. These are industry-wide deal values, including future milestone commitments, rather than cash already received.⁴

The scale is not confined to one company or one agreement. A Biopharma Dealmakers analysis hosted by Nature identified about USD 11 billion in upfront payments and equity investment within roughly USD 100 billion committed by 11 major international drugmakers to selected Chinese deals between January 2020 and June 2025. That is a substantial financial vote of confidence in China's drug-development capabilities.⁵

For patients, the most important evidence is what has reached clinical practice. Fruquintinib, an oral medicine for previously treated bowel cancer, has approvals in China, the US, the EU and the UK. Cilta-cel, a CAR-T treatment developed from a Chinese research programme, is authorised in China, the US and the EU. Aumolertinib, a targeted lung-cancer medicine, secured UK approval in June 2025.⁶

China is also creating new treatment pathways. Its June 2026 approval of satri-cel for a defined group of stomach-cancer patients marked what the Pudong government described as the world's first approved CAR-T therapy for a solid tumour.⁷

The opportunity is increasingly twofold: internationally recognised medicines developed in China, and distinctive treatments that make a specialist assessment in China worth exploring.

2. Cancer-drug and CAR-T costs: China, the UK and the US

What can the price difference look like? These four examples compare a published Chinese hospital price with UK and US prices for the same medicine, or a named medicine in the same treatment class where a same-drug comparison is unavailable. Sterling equivalents make the difference easy to see; original currencies remain alongside them.

These are dated medicine-only price benchmarks from 2023–2026, not current treatment quotes or patients' insured costs. UK/US list prices precede rebates or confidential discounts; they are not NHS patient charges. Same-class products have different indications and are not interchangeable. The 30-day doses are aumolertinib 110 mg, osimertinib 80 mg and zanubrutinib 320 mg daily; China's zanubrutinib figure prorates 120 capsules from a 64-capsule pack. Conversions use ECB rates on 29 October 2026.²⁰²¹²²

Fruquintinib provides a direct comparison: about £850 in China, £3,950 in the UK and £18,923 in the US for the same 21-capsule quantity at these published prices. Zanubrutinib offers a second same-medicine example. For patients looking beyond their home market, treatment location deserves consideration alongside clinical suitability.

3. Which new cancer treatments in China are worth discussing for your diagnosis?

Start with your cancer type, previous treatment and tumour-test results. The options below show where a conversation with a Chinese specialist can be particularly useful.

Stomach cancer: a new CAR-T route for CLDN18.2-positive disease

Worth discussing if: you have advanced stomach or gastro-oesophageal junction cancer, it is CLDN18.2-positive and HER2-negative, and at least two previous treatment lines have failed.²³

Satri-cel trains a patient's own immune cells to recognise CLDN18.2, a protein on the cancer cells. Its significance is the opening of an approved cell-therapy pathway for a solid tumour—a field in which CAR-T has been much harder to develop than in blood cancers. A randomised study showed longer time without cancer progression than the treatments selected for the comparison group.²⁴

For a patient whose current options are narrowing, the useful next step is specific: ask whether your tumour has been tested for CLDN18.2 and whether your records fit the Chinese treatment criteria. That turns an unfamiliar drug name into a focused clinical question.

Multiple myeloma: CAR-T after several previous treatments

Worth discussing if: your myeloma has returned or resisted treatment after several drug regimens. China's cited cilta-cel indication covers patients whose disease has progressed after at least three prior treatment lines, including the specified major drug classes.²⁵

Cilta-cel targets BCMA, a protein found on myeloma cells, using the patient's own engineered T cells. It offers a different way to attack the disease after earlier medicines have stopped controlling it. In a randomised study after one to three previous treatment lines, about 76% of patients assigned to cilta-cel were alive at 30 months, compared with 64% assigned to standard drug combinations.²⁶

That survival result explains the interest in this China-originated therapy. Ask a myeloma specialist whether BCMA CAR-T is an appropriate next step in your treatment sequence, taking account of what you have already received and your current health.

Relapsed lymphoma: another reason to review CD19 CAR-T options

Worth discussing if: you have a relapsed or treatment-resistant B-cell lymphoma, particularly large B-cell lymphoma after two or more systemic treatment lines.²⁷

Relma-cel is a China-approved CAR-T product targeting CD19 on B cells. It adds a locally available product to the specialist treatment discussion; the price comparison above also makes it relevant when reviewing the financial feasibility of a CAR-T pathway. The key question is whether your exact lymphoma subtype and treatment history match its indication—not simply whether you have had chemotherapy before.²⁸²⁹

CAR-T requires specialist hospital care. Serious immune reactions, neurological complications and infections need expert monitoring; cilta-cel also requires follow-up for potentially serious delayed bowel inflammation.³⁰

EGFR-mutated lung cancer: internationally recognised targeted tablets

Worth discussing if: your non-small-cell lung cancer has an EGFR mutation and you need a first targeted treatment or a review after earlier treatment.³¹

Aumolertinib is an oral medicine designed to block the growth signal driven by EGFR. It is approved in China and the UK, giving patients an example of Chinese innovation recognised by the regulator in their home market. The practical appeal combines a biomarker-matched treatment with the published Chinese price shown above.³²³³

Bring your molecular-test report to the discussion. The exact EGFR mutation—and, after progression, any new resistance findings—helps the specialist assess whether aumolertinib or another targeted option fits your next step.

Bowel cancer: an oral option after established treatments

Worth discussing if: you have metastatic colorectal cancer and have already received the usual chemotherapy and relevant targeted treatments.³⁴

Fruquintinib blocks signals that help tumours build their blood supply. Its approvals in the UK, US and EU demonstrate how a China-developed medicine has become part of international cancer care. For someone considering continued treatment in China, it also provides a direct price comparison in the table: the same medicine, strength and capsule quantity across all three markets.^35363738

Ask whether fruquintinib belongs in your treatment sequence and what ongoing prescribing and monitoring would involve.

Triple-negative breast cancer: a targeted delivery approach after relapse

Worth discussing if: you have inoperable locally advanced or metastatic triple-negative breast cancer after at least two systemic treatments have failed.³⁹

Sacituzumab tirumotecan, or sac-TMT, is an antibody–drug conjugate. In plain English, it links an anticancer drug to an antibody that recognises TROP2, helping deliver the drug to cancer cells. It has a Chinese approval for a defined previously treated triple-negative breast-cancer population.⁴⁰⁴¹

In a randomised study, patients receiving sac-TMT lived a median 6.7 months without cancer progression, compared with 2.5 months with chemotherapy. For patients whose cancer has returned, that is a concrete reason to ask about this different treatment approach and how it fits with medicines already tried.⁴²

Already know your diagnosis? Contact MediConnex to discuss a specialist review of the treatment options relevant to you.

4. What is driving the progress—and what comes next?

The pattern behind these advances is clear: greater research investment, hospital-based clinical development and international partnerships. China's R&D growth, the early cilta-cel programme across four Chinese hospitals and the scale of overseas licensing show those strengths coming together.⁴³⁴⁴⁴⁵

The next wave reaches beyond today's approved medicines:

• NK and CAR-NK cells explore another arm of the immune system. Natural killer cells can attack abnormal cells; CAR engineering adds recognition of a selected cancer target. Donor-derived approaches raise the prospect of preparing cell treatments in advance rather than manufacturing a separate product from every patient's own cells. Chinese researchers have already tested a CLDN18.2 CAR-NK approach in an early study of nine patients with advanced gastric or pancreatic cancers.⁴⁶
• CIK cells are immune cells expanded in the laboratory and studied alongside other cancer treatments. A randomised study involving 90 patients at eight Chinese hospitals tested CIK cells with chemotherapy in advanced squamous lung cancer—evidence of a clinical research programme extending beyond laboratory work.⁴⁷
• PD-1/CTLA-4-armoured DC vaccines: recognising cancer and releasing immune brakes. Shanghai's BaizeDC research programme loads a patient's dendritic cells with tumour-antigen mRNA and equips them to produce an antibody targeting both PD-1 and CTLA-4. The aim is to help T cells identify cancer while countering signals that hold back their response—an approach being explored after solid-tumour surgery. A 2024 conference abstract reported tumour-specific T-cell responses in three of four patients. This early human evidence supports further development; whether the approach reduces recurrence requires larger studies.⁴⁸
• Personalised DC vaccines: building on a patient's tumour profile. A separate Beijing Tiantan Hospital study, published in Nature Communications in 2026, treated 11 people with newly diagnosed glioblastoma using a personalised neoantigen-loaded DC vaccine after surgery and standard radiochemotherapy. The early study demonstrated tumour-specific immune responses, with safety as its primary endpoint—a concrete example of this approach reaching human research.⁴⁹

These remain investigational approaches, but they are already being studied in people, not just in the laboratory. They open important questions: can immune treatment reach more tumour types, become easier to manufacture, or better complement established care?

If established options are running short, ask about the relevant research directions and whether a suitable clinical study is available. A specialist discussion can connect your diagnosis with the science that matters to it.

5. Advanced treatment, with affordability and access in view

China's appeal combines medical innovation with a healthcare system focused on bringing treatment within reach of more people. National drug-price negotiations and regular updates to the reimbursable medicines list are designed to lower prices and broaden access to new therapies.⁵⁰

For overseas patients, the published prices above make affordability a meaningful part of a specialist treatment review. The starting point is a doctor's assessment of the options that fit your diagnosis; approved medicines require prescribing, and cell-therapy infusions belong in appropriately equipped hospitals.

Could a China-developed cancer treatment be right for you? Contact MediConnex to explore a specialist review of your treatment options in China.

Discuss a specialist review

Sources